Kymera Therapeutics (KYMR) shares were up 2.5% in recent Monday trading after Wells Fargo upgraded the stock's rating to overweight.
The firm has a price target of $57 for the company.
Trading volume stood at over 187,000 shares against a daily average of about 418,000 shares.
Price: 48.01, Change: +1.16, Percent Change: +2.47